Tresiba will be available in the FlexTouch pen, which has no push-button extension, and will be offered in two concentrations enabling maximum doses of 80 units and 160 units per single injection, respectively, according to Novo Nordisk. Hobbs said Tresiba also offers other patient benefits such as eight weeks of in-use time at room temperature.

Regarding Tresiba's performance versus Sanofi's insulin offering, Lantus, Hobbs said Tresiba's clinical program was designed "head-to-head versus them, so we feel like we have the benefits that are going to enable us to fight a good fight against that market leader."

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday